# US 2019/0293662 A1 · Gfap derivatives for stroke diagnostics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0293662 A1
- Document ID: US20190293662A1
- Status: Published application
- Kind: A1
- Application number: 16/462,924
- Filed: 2017-11-23
- Published: 2019-09-26
- Earliest claimed: 2016-11-23
- Applicants: Randox Laboratories Ltd; Randox Teoranta
- Inventors: Ciaran Richardson; Ivan McConnell; John Lamont; Stephen Peter Fitzgerald
- Web page: https://patentgrep.com/patent/US20190293662A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- C07K 16/18: against material from animals or humans
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- G01N 2800/2871: Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Described are methods and kits for diagnosing stroke using GFAP derivatives.

## Claims

### Claim 1

An immunoanalytical method of diagnosing or supporting the diagnosis of stroke in a subject comprising taking a sample from the subject and measuring the amount of a GFAP derivative present in the sample the method incorporating an antibody which binds to an epitope incorporated in the sequence ETRASERAEMME of a GFAP derivative, in which an amount of a GFAP derivative in the sample bound by the antibody which is greater than the amount of a GFAP control is indicative of stroke.

### Claim 2 (depends on 1)

The method of claim 1 in which the stroke is haemorrhagic stroke, haemorrhagic transformation or fatal ischaemic stroke.

### Claim 3 (depends on 1)

The method of claim 1 in which the GFAP control level is one that has been measured in a healthy patient or a healthy population of patients, or has been derived from a population of patients categorised as one or more of TIA, stroke mimic or ischaemic stroke.

### Claim 4

A method comprising using GFAP derivatives as markers of haemorrhagic stroke, haemorrhagic transformation or fatal ischaemic stroke.

### Claim 5 (depends on 4)

The method of claim 4 in which the GFAP derivative has a molecular weight of about 44 kDa and which is bound by an antibody which recognises the epitope sequence ETRASERAEMME within the GFAP derivative.

### Claim 6 (depends on 5)

The method of claim 5 in which the antibody binds to at least one amino acid within the sequence SERA of the GFAP derivative.

### Claim 7

An antibody which binds to an epitope of a GFAP species incorporated in the sequence ETRASERAEMME.

### Claim 8 (depends on 7)

The antibody of claim 7 in which the epitope comprises a least one amino acid from the sequence SERA.

### Claim 9 (depends on 7)

The antibody of claim 7 in which the GFAP species is a GFAP derivative of molecular weight less than native GFAP without post translational modification and has a molecular weight of about 44 kDa.

### Claim 10 (depends on 7)

The antibody of claim 7 which is attached to or adsorbed on the surface of a solid-state device.

### Claim 11 (depends on 10)

The antibody of claim 10 in which the solid-state device is a biochip.

### Claim 12 (depends on 7)

A method comprising using an antibody of claim 7 in stroke diagnosis.

### Claim 13 (depends on 12)

The method of claim 12 in which the stroke is haemorrhagic stroke, haemorrhagic transformation or fatal ischaemic stroke.

### Claim 14 (depends on 7)

A kit which incorporates an antibody of claim 7.

### Claim 15 (depends on 14)

The kit of claim 14 which incorporates a further antibody that binds to an epitope a GFAP species with the proviso that it does not bind to an amino acid within the sequence ETRASERAEMME.

### Claim 16

A method of using a capture and detector antibody each binding to a discrete epitope of non-overlapping amino acid residues comprised within the sequence 60 to 383 corresponding to GFAP Uniprot numbers P14136-1, P14136-2, and P14136-3 in an immunoassay method for diagnosing or supporting the diagnosis of stroke.

### Claim 17 (depends on 16)

The method of claim 16 in which one of the capture and detector antibodies binds to an epitope of GFAP within the sequence ETRASERAEMME.

### Claim 18 (depends on 16)

The method of claim 16 in which one of GF9 and 4A1 1 is the capture antibody and the other is the detector antibody.

### Claim 19 (depends on 16)

The method of claim 16 in diagnosing or supporting the diagnosis of haemorrhagic stroke, haemorrhagic transformation or fatal ischaemic stroke.
